Transcatheter Aortic Valve Implantation for Degenerative Aortic Valve Regurgitation Long After Heart Transplantation

Zanuttini, Davide; Armellini, Ilaria; Bisceglia, Teodoro; Spedicato, Leonardo; Bernardi, Guglielmo; Muzzi, Rodolfo; Proclemer, Alessandro; Livi, Ugolino

doi:10.1016/j.athoracsur.2013.03.040

Cited by 17 publications

(17 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Transcather aortic valve replacement (TAVR) offers a minimally invasive alternative in this high‐risk population. A small but growing number of cases of TAVR after heart transplantation in high‐risk patients have been reported in the last 10 years; we now present such a case to further support the role of TAVR in this patient population 3‐8 …”

Section: Introductionsupporting

confidence: 54%

See 1 more Smart Citation

Transcatheter aortic valve replacement 24 years after cardiac transplantation

et al. 2020

View full text Add to dashboard Cite

As patient survival after cardiac transplantation has improved over the course of the last several decades, clinicians are now faced with late complications. This includes aortic stenosis which, traditionally, has been treated with reoperative sternotomy and aortic valve replacement. Transcather aortic valve replacement (TAVR) offers a minimally invasive alternative in this high‐risk population. A small but growing number of cases of TAVR after heart transplantation in high‐risk patients have been reported in the last 10 years; we now present a case of aortic valve replacement via a transcatheter approach 24 years after cardiac transplantation.

show abstract

Section: Introductionsupporting

confidence: 54%

“…Nonetheless, in elderly or high‐risk patients, TAVR is a well‐supported alternative to surgical replacement. A review of the literature demonstrates only a handful of other documented reports that describe the use of TAVR in this clinical scenario 3‐8 . Our case adds to this small, but increasing, body of literature.…”

Section: Discussionmentioning

confidence: 66%

Transcatheter aortic valve replacement 24 years after cardiac transplantation

et al. 2020

View full text Add to dashboard Cite

show abstract

“…A delay in diagnosis may cause significant morbidity and mortality due to cerebral embolisation, acute renal failure, sepsis and congestive heart failure. TAVI-PVE has in general been treated conservatively due to the inherent high operative risk (19,21). In Puls et al cohort study PVE mortality was reported about 40% with conservative treatment (20).…”

Section: Discussionmentioning

confidence: 99%

Prosthetic valve endocarditis after transcatheter aortic valve implantation-diagnostic and surgical considerations

et al. 2016

View full text Add to dashboard Cite

Prosthetic valve endocarditis (PVE) after transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement (SAVR) is a potential life threatening complication. Better understanding of the incidence, predictors, clinical presentation, diagnostic measures, complications and management of PVE may help improve TAVI long-term outcome. We report a case of TAVI-PVE in an 80-year-old high risk patient in whom SAVR was successfully performed. We have reviewed literature regarding TAVI-PVE.

show abstract

“…Zanuttini et al (1) in 2013 reported a transfemoral TAVI in a high-risk 75-year-old HTx recipient (EuroSCORE 36%) 14 years after HTx. Praetere et al (2) reported transapical TAVI in a 77-year-old high-risk HTx recipient with severely depressed left ventricular ejection fraction (LVEF) (25%), EuroSCORE 26.7% and ischemic heart disease.…”

Section: Introductionmentioning

confidence: 99%

Transcatheter aortic valve implantation in a young heart transplant recipient crossing the traditional boundaries

Ahmad¹,

Terkelsen²,

Terp³

et al. 2016

J. Thorac. Dis.

View full text Add to dashboard Cite

Transcatheter aortic valve implantation (TAVI) is an established therapeutic alternative to surgical aortic valve replacement (SAVR) in high-risk or inoperable patients with symptomatic aortic valve stenosis. Hitherto, TAVI is not recommended in young and low-intermediate risk patients. However, TAVI may also serve as an alternative to SAVR in selected young patients, e.g., patients who have previously undergone multiple cardiac surgery procedures. We report a case of trans-femoral TAVI in a 25-year-old heart transplant (HTx) recipient with prior surgery for congenital heart disease.

show abstract

Transcatheter Aortic Valve Implantation for Degenerative Aortic Valve Regurgitation Long After Heart Transplantation

Cited by 17 publications

References 8 publications

Transcatheter aortic valve replacement 24 years after cardiac transplantation

Transcatheter aortic valve replacement 24 years after cardiac transplantation

Prosthetic valve endocarditis after transcatheter aortic valve implantation-diagnostic and surgical considerations

Transcatheter aortic valve implantation in a young heart transplant recipient crossing the traditional boundaries

Contact Info

Product

Resources

About